ARS Pharmaceuticals, Inc. (SPRY)
- Previous Close
8.89 - Open
8.94 - Bid 8.97 x 100
- Ask 9.01 x 100
- Day's Range
8.89 - 9.06 - 52 Week Range
2.55 - 11.27 - Volume
346,853 - Avg. Volume
727,481 - Market Cap (intraday)
870.12M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.57 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.00
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ars-pharma.comRecent News: SPRY
Performance Overview: SPRY
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPRY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPRY
Valuation Measures
Market Cap
861.40M
Enterprise Value
633.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
28.22k
Price/Book (mrq)
3.73
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.54%
Return on Equity (ttm)
-20.49%
Revenue (ttm)
10k
Net Income Avi to Common (ttm)
-49.7M
Diluted EPS (ttm)
-0.57
Balance Sheet and Cash Flow
Total Cash (mrq)
223.63M
Total Debt/Equity (mrq)
0.10%
Levered Free Cash Flow (ttm)
-34.37M
Research Analysis: SPRY
Company Insights: SPRY
SPRY does not have Company Insights